Project Grant R01HL175954
Award Date
5/1/25
Completion Date
2/28/29
Dollars Obligated
$705K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), is funded under the Cardiovascular Diseases Research program (CFDA 93.837). The $733,848 award to the University of Pittsburgh will support research into developing selective inhibitors of the MLCL/cytochrome c peroxidase complex, which is believed to be a primary mechanism underlying the pathogenesis of Barth syndrome (BTHS). BTHS is an X-linked disorder...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $890,723 to Cleveland State University (CSU) to develop novel mitochondria-targeting peptides (MTPs) as a therapeutic intervention for Barth syndrome (BTHS). BTHS is a rare genetic disorder characterized by mitochondrial dysfunction and cardiomyopathy. The project aims to address the critical need for effective treatments...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $749,769 to The Johns Hopkins University to study the factors underlying the failure of pluripotent stem cell-derived cardiomyocytes (PSC-CMs) to fully mature. The research aims to identify a critical gene regulatory network driving this premature maturation arrest, with the goal of developing a transcriptome-based strategy to...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), awarded a $107,298 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to The Johns Hopkins University to conduct research on the molecular regulation of the cardiac-specific form of the mitochondrial phospholipid cardiolipin. The research aims to determine the mechanisms underlying the specific regulation of cardiac cardiolipin, including the role of the enzyme tafazzin, the...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will support research into the Hippo-YAP signaling pathway and its role in cardiac regenerative repair. The $693,261 award, effective January 10, 2025 through December 31, 2028, aims to develop gene therapy strategies that can enhance cardiac function and promote regenerative responses following myocardial infarction. The research will...
This $642,754.00 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Program (CFDA 93.837) supports research to understand the mechanisms behind hematopoietic stem cell (HSC) functional decline after bone marrow transplantation. The key objectives are to: 1) investigate why abnormal mitochondria in HSCs are not removed after transplantation and the impact on HSC functions, and 2) explore the effects of mitochondrial defects on...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research Program (CFDA 93.837), provides $165,672 to The Leland Stanford Junior University to investigate the role of cardiac troponin I (cTnI) in regulating mitochondrial function and its impact on cardiomyopathy. The research aims to: 1) determine how cTnI phosphorylation and truncation affect mitochondrial ATP synthase binding and respiration, and 2) evaluate the...
This Project Grant award of $631,261 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to elucidate the role of autophagy and mitochondrial quality control mechanisms, including mitophagy, in senescence of the heart and cardiomyocytes. The key objectives are to: 1) test whether downregulation of autophagy directly induces senescence in cardiomyocytes through YAP-dependent mechanisms, 2) test whether...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,204,160 to evaluate the AMPK-BACH1-NRF2 pathway as a potential therapeutic target for inherited dilated cardiomyopathy (DCM). The primary goal is to determine if activating this signaling pathway can restore contractile function in multiple forms of inherited DCM, including those caused by mutations in myofilament and...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $144,362 to support research on the immunologic mechanisms underlying Chagas cardiomyopathy pathogenesis. The primary aims are to use cutting-edge single-cell RNA sequencing and spatial transcriptomics of human samples to characterize the immune cell alterations and pathways mediating cardiac damage in Chagas disease. Additionally, the...